Academic Accommodations for Attention Deficit Hyperactivity Disorder (ADHD)

Phase-Based Progress Estimates
3
Effectiveness
3
Safety
FIU Center for Childern and Families, Miami, FL
Attention Deficit Hyperactivity Disorder (ADHD)
Academic Accommodations - Behavioral
Eligibility
< 18
All Sexes
What conditions do you have?
Select

Study Summary

This study is the first to systematically evaluate the efficacy of single and combined academic accommodation, behavioral treatment, and medication treatment in a large sample of children with ADHD. Using a scientifically rigorous, cross-over design the impact of these approaches on ecologically valid measures of outcome (on-task behavior, quiz scores, academic productivity) will be assessed to inform effective school intervention.

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Other trials for Attention Deficit Hyperactivity Disorder (ADHD)

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Through study completion, a maximum of eight weeks

Through study completion, a maximum of eight weeks
Behavioral frequency count of rule violations
Quiz Scores
Seatwork completion

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Attention Deficit Hyperactivity Disorder (ADHD)

Trial Design

5 Treatment Groups

General Classroom
1 of 5
Academic accommodations
1 of 5
Positive Behavior Support Classroom
1 of 5
Methylphenidate ER (.3 mg/kg dose)
1 of 5
Placebo
1 of 5
Active Control
Experimental Treatment
Non-Treatment Group

288 Total Participants · 5 Treatment Groups

Primary Treatment: Academic Accommodations · Has Placebo Group · Phase 4

Academic accommodationsExperimental Group · 4 Interventions: Placebo, General Classroom, Methylphenidate Hydrochloride ER, Behavioral classroom · Intervention Types: Drug, Behavioral, Drug, Behavioral
Positive Behavior Support ClassroomExperimental Group · 3 Interventions: Placebo, Methylphenidate Hydrochloride ER, Academic Accommodations · Intervention Types: Drug, Drug, Behavioral
Methylphenidate ER (.3 mg/kg dose)Experimental Group · 3 Interventions: General Classroom, Behavioral classroom, Academic Accommodations · Intervention Types: Behavioral, Behavioral, Behavioral
General ClassroomActiveComparator Group · 3 Interventions: Placebo, Methylphenidate Hydrochloride ER, Academic Accommodations · Intervention Types: Drug, Drug, Behavioral
PlaceboPlaceboComparator Group · 3 Interventions: General Classroom, Behavioral classroom, Academic Accommodations · Intervention Types: Behavioral, Behavioral, Behavioral
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, a maximum of eight weeks
Closest Location: FIU Center for Childern and Families · Miami, FL
Photo of Miami 1Photo of Miami 2Photo of Miami 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching Attention Deficit Hyperactivity Disorder (ADHD)
0 CompletedClinical Trials

Who is running the clinical trial?

Florida International UniversityLead Sponsor
84 Previous Clinical Trials
14,927 Total Patients Enrolled
13 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
1,650 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Eligibility Criteria

Age < 18 · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.